AAO: Intranasal Tear Neurostimulator Safe for Dry Eye

Share this content:
AAO: Intranasal Tear Neurostimulator Safe for Dry Eye
AAO: Intranasal Tear Neurostimulator Safe for Dry Eye

(HealthDay News) -- An intranasal tear neurostimulator (ITN) is safe and effective for increasing tear production among individuals with dry eye, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held Nov. 11 to 14 in New Orleans.

Edward J. Holland, M.D., from the University of Cincinnati, and colleagues examined the safety and effectiveness of the ITN for increasing tear production in subjects with dry eye. Forty-eight patients were enrolled in a one-day, randomized crossover study with three applications (active intranasal, extranasal, and sham intranasal controls) in a randomized sequence; differences in Schirmer scores were assessed. In a second study, 97 patients were enrolled in a 180-day, open-label trial to examine the differences in Schirmer scores for ITN stimulation versus no stimulation.

The researchers found that the mean Schirmer scores were significantly greater with active intranasal versus extranasal and sham applications in the first study (25±10.7 mm versus 9.5±8.2 mm and 9.2±7.3 mm, respectively). In the second study, at day 180, Schirmer scores were significantly greater with ITN stimulation versus no stimulation (17.3±12 mm versus 7.9±6.4 mm). There were no reports of serious device-related adverse events.

"I believe this will be a very beneficial treatment option for our dry eye patients" Holland said in a statement. "It's an innovative technology that effectively and safely increases tear production."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »